African-American TOMM40'523-APOE haplotypes are admixture of West African and Caucasian alleles

Background: Several studies have demonstrated a lower apolipoprotein E4 (APOE e4) allele frequency in African-Americans, but yet an increased age-related prevalence of AD. An algorithm for prevention clinical trials incorporating TOMM40'523 (Translocase of Outer Mitochondria Membrane) and APOE...

Full description

Bibliographic Details
Main Authors: Roses, A., Lutz, M., Saunders, A., Goldgaber, D., Saul, R., Sundseth, S., Akkari, Patrick, Roses, S., Gottschalk, W., Whitfield, K., Vostrov, A., Hauser, M., Allingham, R., Burns, D., Chiba-Falek, O., Welsh-Bohmer, K.
Format: Journal Article
Published: Elsevier Inc. 2014
Online Access:http://hdl.handle.net/20.500.11937/15480
Description
Summary:Background: Several studies have demonstrated a lower apolipoprotein E4 (APOE e4) allele frequency in African-Americans, but yet an increased age-related prevalence of AD. An algorithm for prevention clinical trials incorporating TOMM40'523 (Translocase of Outer Mitochondria Membrane) and APOE depends on accurate TOMM40'523-APOE haplotypes. Methods: We have compared the APOE and TOMM40'523 phased haplotype frequencies of a 9.5 kb TOMM40/APOE genomic region in West African, Caucasian, and African-American cohorts. Results: African-American haplotype frequency scans of poly-T lengths connected in phase with either APOE e4 or APOE e3 differ from both West Africans and Caucasians and represent admixture of several distinct West African and Caucasian haplotypes. A new West African TOMM40'523 haplotype, with APOE e4 connected to a short TOMM40'523 allele, is observed in African-Americans but not Caucasians. Conclusion: These data have therapeutic implications for the age of onset risk algorithm estimates and the design of a prevention trial for African-Americans or other mixed ethnic populations.